The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The geographic atrophy market has been comprehensively analyzed in IMARC’s new report titled “Geographic Atrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”. Geographic atrophy is an advanced form of dry age-related macular degeneration that affects the retina, a part of the eye that sends information to the brain to enable sight. In this stage, the damage is so severe that it causes blind spots in the patient’s central vision. A patient can have both wet and dry age-related macular degeneration simultaneously and develop geographic atrophy independently of having wet age-related macular degeneration. This disease leads to sharply demarcated atrophy of the outer retinal tissue, retinal pigment epithelium, and choriocapillaris. The common symptoms experienced by patients are central vision loss, difficulty in low-light conditions, and trouble seeing colors. Initially, the sign is identified while reading when one or several letters are missing from a word or when looking at faces, a small region of the face is not clearly visible. Over several years, geographic atrophy causes the central vision to diminish and the visual acuity comes down to 20/200. However, it does not usually affect peripheral vision. Geographic atrophy can be identified by an ophthalmologist using retinal imaging and a dilated examination. In a dilated exam, geographic atrophy appears as a patch of the retina without dark melanin pigment. Imaging techniques can also be used to detect geographic atrophy, including optical coherence tomography (OCT), retinal color photographs, autofluorescence imaging, etc.
The increasing prevalence of retinal disorders along with the expanding geriatric population is primarily driving the geographic atrophy market. Additionally, the rising incidences of obesity and cardiovascular diseases (CVDs) on account of changing dietary patterns, sedentary lifestyles, and unhealthy habits like smoking are further creating a positive outlook for the market. In line with this, the escalating usage of smartphones, laptops, televisions, etc., which is leading to prolonged and excessive screen time, is also propelling the market growth. Moreover, the introduction of retinal gene therapies, which involve injecting adeno-associated virus (AAV) into the body to prevent the development of abnormal blood vessels, is further acting as a significant growth-inducing factor. Besides this, the widespread adoption of autofluorescence imaging technology to visualize the retinal pigment epithelium (RPE) in order to assess the progression rate of the disease is also bolstering the global market. Additionally, several key players are making substantial investments in developing imaging technologies that will contribute to the understanding of the genesis and pathophysiological mechanisms of geographic atrophy. This, in turn, is positively influencing the market growth. Numerous other factors, such as extensive R&D activities for launching innovative and effective drugs and the increasing expenditure on healthcare to facilitate access to affordable treatment options, are expected to drive the geographic atrophy market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the geographic atrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for geographic atrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the geographic atrophy market in any manner.
Time Period of the Study
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current geographic atrophy marketed drugs and late-stage pipeline drugs.
Late-Stage Pipeline Drugs
Geographic Atrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
Pregnancy Detection Kits Market by Product (Home Pregnancy Tests (HPT), Digital Devices, and Others), Test Type (Urine Test for HCG, Blood Test for HCG, and Others), End User (Household, Gynecology Clinics, Hospitals), and Region 2023-2028
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at